CytoAgents
Pittsburgh, US · Founded 2018 · Delaware corporation · 1 known investors
CytoAgents is a clinical-stage biopharmaceutical company developing CTO1681, an oral prostacyclin/prostaglandin analogue that modulates cytokine-driven inflammation while preserving immune function. Its pipeline targets indications including CAR T-cell therapy-related cytokine release syndrome, pulmonary arterial hypertension, asthma, and atopic dermatitis.
Founders & leadership
CM
Catherine MottDirector
TW
Teresa WhalenExecutive Officer, Director
AM
Anthony McCarleyDirector
JF
John FriedmanDirector
SM
Stanley MarksDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$7MraisedMay 2023 · 23 investors · Other Health CareRule 506(b)
▶$7MraisedMay 2023 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Roy PriebExecutive Officer
- Robert L FerrisDirector
- Stanley MarksDirector
- Teresa WhalenExecutive Officer, Director
- Anthony McCarleyDirector
- Catherine MottDirector
- Offering amount
- $15.2M
- Amount sold
- $7M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$6.1MraisedAug 2021 · 23 investors · Other Health CareRule 506(b)
▶$6.1MraisedAug 2021 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Catherine MottDirector
- Teresa WhalenExecutive Officer, Director
- Anthony McCarleyDirector
- John FriedmanDirector
- Stanley MarksDirector
- Offering amount
- $6.5M
- Amount sold
- $6.1M
- Minimum investment
- $10K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.